The chronic effects of triacylglycerol structure of palm oil on glucose homeostasis, insulin secretion and sensitivity and lipid metabolism

The chronic effects of triacylglycerol structure of palm oil in healthy adults on glucose homeostasis, insulin secretion and sensitivity and lipid metabolism: a single-blind, randomized crossover trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16669399

Enrollment

Registered

2011-09-19

Start date

2011-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease Circulatory System Ischaemic heart diseases

Interventions

The dietary intervention will involve provision of 20% energy intake (approximately 45 g/d if based on a 2000 kcal basic diet) from the three test fats - palm olein (control), interesterified palm ol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy male and female participants, aged between 20 and 50 years

Exclusion criteria

Exclusion criteria: 1. Medical history of myocardial infarction, angina, thrombosis, stroke, cancer or diabetes 2. Participants with metabolic syndrome as defined by the International Diabetes Federation (http://www.idf.org/webdata/docs/MetS_def_update2006.pdf) 3. Underweight [Body mass index (BMI) 7.0 mmol /L 5. Plasma triacylglycerol > 3 mmol /L 6. Plasma glucose > 7 mmol /L 7. Current use of antihypertensive, lipid lowering, insulin/glucose-modulating medication 8. Alcohol intake exceeding a moderate intake (> 21 units/week for males and > 14 units/week for females)

Design outcomes

Primary

Measure	Time frame
1. ß-cell function (measured as the increments in C-peptide response to a mixed meal) will be measured at fasting, 10, 20, 30, 60, 90 and 120 minutes postprandially. These measurements will be taken at the baseline visit, 6, 12 and 18 week visits. 2. C-peptide will also be measured at fasting at the 3, 9 and 15 week visits. C-peptide will be measured using a solid-phase, two-site chemiluminescence immunoassay	—

Measure

Time frame

1. ß-cell function (measured as the increments in C-peptide response to a mixed meal) will be measured at fasting, 10, 20, 30, 60, 90 and 120 minutes postprandially. These measurements will be taken at the baseline visit, 6, 12 and 18 week visits. 2. C-peptide will also be measured at fasting at the 3, 9 and 15 week visits. C-peptide will be measured using a solid-phase, two-site chemiluminescence immunoassay

—

Secondary

Measure	Time frame
1. Insulin and glucose concentrations will be measured at fasting (in duplicate separated by a 5-minute interval), 10, 20, 30, 60, 90 and 120 minutes postprandially at the baseline visit, 6, 12 and 18 week visits. 2. Insulin and glucose concentrations will also be measured at fasting (in duplicate as described above) at the 3, 9 and 15 week visits. Insulin will be measured using a solid phase, two-site chemiluminescence immunoassay and glucose will be measured using an endpoint enzymatic reaction.	—

Measure

Time frame

1. Insulin and glucose concentrations will be measured at fasting (in duplicate separated by a 5-minute interval), 10, 20, 30, 60, 90 and 120 minutes postprandially at the baseline visit, 6, 12 and 18 week visits. 2. Insulin and glucose concentrations will also be measured at fasting (in duplicate as described above) at the 3, 9 and 15 week visits. Insulin will be measured using a solid phase, two-site chemiluminescence immunoassay and glucose will be measured using an endpoint enzymatic reaction.

—

Countries

Malaysia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026